+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Polycystic Kidney Disease Drugs Market 2021-2025- Product Image

Global Polycystic Kidney Disease Drugs Market 2021-2025

  • ID: 5300881
  • Report
  • February 2021
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • MORE
Global Polycystic Kidney Disease Drugs Market 2021-2025

The publisher has been monitoring the polycystic kidney disease drugs market and it is poised to grow by $485.71 mn during 2021-2025 progressing at a CAGR of 7% during the forecast period. The report on polycystic kidney disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of chronic kidney diseases, increasing R&D for developing new drugs and special regulatory designations. In addition, high prevalence of chronic kidney diseases is anticipated to boost the growth of the market as well.

The polycystic kidney disease drugs market analysis includes type segment and geographical landscapes.

The polycystic kidney disease drugs market is segmented as below:

By Type
  • ADPKD
  • ARPKD
By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the special regulatory designations as one of the prime reasons driving the polycystic kidney disease drugs market growth during the next few years. Also, favorable reimbursement policies and growing awareness about kidney diseases will lead to sizable demand in the market.

Thereport on polycystic kidney disease drugs market covers the following areas:
  • Polycystic kidney disease drugs market sizing
  • Polycystic kidney disease drugs market forecast
  • Polycystic kidney disease drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs market vendors that include CorePharma LLC, Galapagos NV, Hikma Pharmaceuticals Plc, Johnson & Johnson, Kadmon Holdings Inc., Merck & Co. Inc., Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Reata Pharmaceuticals Inc., and Sanofi. Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • ADPKD - Market size and forecast 2020-2025
  • ARPKD - Market size and forecast 2020-2025
  • Market opportunity by Type
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • Otsuka Holdings Co. Ltd.
  • Palladio Biosciences Inc.
  • Reata Pharmaceuticals Inc.
  • Sanofi
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Type - Market share 2020-2025 (%)
  • Comparison by Type
  • ADPKD - Market size and forecast 2020-2025 ($ million)
  • ADPKD - Year-over-year growth 2020-2025 (%)
  • ARPKD - Market size and forecast 2020-2025 ($ million)
  • ARPKD - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • CorePharma LLC - Overview
  • CorePharma LLC - Product and service
  • CorePharma LLC - Key offerings
  • CorePharma LLC - Key customers
  • CorePharma LLC - Segment focus
  • Galapagos NV - Overview
  • Galapagos NV - Business segments
  • Galapagos NV - Key offerings
  • Galapagos NV - Key customers
  • Galapagos NV - Segment focus
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Key customers
  • Hikma Pharmaceuticals Plc - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Kadmon Holdings Inc. - Overview
  • Kadmon Holdings Inc. - Business segments
  • Kadmon Holdings Inc. - Key offerings
  • Kadmon Holdings Inc. - Key customers
  • Kadmon Holdings Inc. - Segment focus
  • Merck & Co. Inc. - Overview
  • Merck & Co. Inc. - Business segments
  • Merck & Co. Inc. - Key offerings
  • Merck & Co. Inc. - Key customers
  • Merck & Co. Inc. - Segment focus
  • Otsuka Holdings Co. Ltd. - Overview
  • Otsuka Holdings Co. Ltd. - Business segments
  • Otsuka Holdings Co. Ltd. - Key offerings
  • Otsuka Holdings Co. Ltd. - Key customers
  • Otsuka Holdings Co. Ltd. - Segment focus
  • Palladio Biosciences Inc. - Overview
  • Palladio Biosciences Inc. - Product and service
  • Palladio Biosciences Inc. - Key offerings
  • Palladio Biosciences Inc. - Key customers
  • Palladio Biosciences Inc. - Segment focus
  • Reata Pharmaceuticals Inc. - Overview
  • Reata Pharmaceuticals Inc. - Business segments
  • Reata Pharmaceuticals Inc. - Key offerings
  • Reata Pharmaceuticals Inc. - Key customers
  • Reata Pharmaceuticals Inc. - Segment focus
  • Sanofi - Overview
  • Sanofi - Business segments
  • Sanofi - Key offerings
  • Sanofi - Key customers
  • Sanofi - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • MORE
The publisher recognizes the following companies as the key players in the global polycystic kidney disease drugs market: CorePharma LLC, Galapagos NV, Hikma Pharmaceuticals Plc, Johnson & Johnson, Kadmon Holdings Inc., Merck & Co. Inc., Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Reata Pharmaceuticals Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rising availability of favorable reimbursement policies.'

According to the report, one of the major drivers for this market is the high prevalence of chronic kidney diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • Otsuka Holdings Co. Ltd.
  • Palladio Biosciences Inc.
  • Reata Pharmaceuticals Inc.
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll